MediciNova, Inc. Announces Positive Results In NASH Mouse Model With MN-001 And Prepares To Initiate Phase 2 Trial In The U.S.

Published: Jan 14, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Jan. 14, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive results from a study that examined the potential clinical efficacy of MN-001 for the treatment of NASH (nonalcoholic steatohepatitis).

Help employers find you! Check out all the jobs and post your resume.

Back to news